Cancer is caused by abnormal proliferation of cells and aberrant recognition of the immune system. According to recent studies, natural products are most likely to be effective at preventing cancer without causing any noticeable complications. Among the bioactive flavonoids found in fruits and vegetables, quercetin is known for its anti-inflammatory, antioxidant, and anticancer properties. This review aims to highlight the potential therapeutic effects of quercetin on some different types of cancers including blood, lung and prostate cancers.

No abstract

Multiple sclerosis (MS) is an inflammatory disease related to the central nervous system (CNS) with a significant global burden. In this illness, the immune system plays an essential role in its pathophysiology and progression. The currently available treatments are not recognized as curable options and, at best, might slow the progression of MS injuries to the CNS. However, stem cell treatment has provided a new avenue for treating MS. Stem cells may enhance CNS healing and regulate immunological responses. Likewise, stem cells can come from various sources, including adipose, neuronal, bone marrow, and embryonic tissues. Choosing the optimal cell source for stem cell therapy is still a difficult verdict. A type of stem cell known as mesenchymal stem cells (MSCs) is obtainable from different sources and has a strong immunomodulatory impact on the immune system. According to mounting data, the umbilical cord and adipose tissue may serve as appropriate sources for the isolation of MSCs. Human amniotic epithelial cells (hAECs), as novel stem cell sources with immune-regulatory effects, regenerative properties, and decreased antigenicity, can also be thought of as a new upcoming contender for MS treatment. Overall, the administration of stem cells in different sets of animal and clinical trials has shown immunomodulatory and neuroprotective results. Therefore, this review aims to discuss the different types of stem cells by focusing on MSCs and their mechanisms, which can be used to treat and improve the outcomes of MS disease.

Background Atopy is used to describe the genetic tendency to IgE-mediated responses. Many factors contribute to predisposing individuals to atopy, including cytokines. IL-7 is a cytokine that mediates hypersensitivity responses and proliferation of T cells and has a polymorphic gene for its receptor (CD127). These different alleles may affect the signaling cascade or alter the production of inflammatory cytokines, which may exacerbate atopic conditions, including asthma and allergy. Objective Primary objective of our study aimed to explore the linkage between IL-7Rα gene polymorphism at the SNP of rs6897932 and the risk of atopic diseases. Evaluating the association of IL-7Rα SNP of rs987106 and also serum levels of IL-7 with the risk of atopy are among the secondary objectives. Methods To seek possible relations of SNPs rs6897932 and rs987106 with the risk of atopy, we recruited 101 atopic patients and 201 sex-age matched healthy controls from Iranian ethnicity and used the data for evaluation. Results Statistical analysis revealed that the T allele variant of IL-7Rα gene at the SNP of rs6897932 is more prevalent among the atopic patients (53.5%) than in the controls (26.9%) and have a considerable association with the disease (p < 0.0001, OR: 3.13 (95% CI- 1.90 to 5.16)). Also, the higher frequency of T allele variant of rs987106 in atopic patients (64.4%) versus control (31.3%) was associated with around a 4-fold increase in the risk of atopy (p < 0.0001, OR: 3.95 (95% CI- 2.39 to 6.55)). However, there was no significant association between IL-7 serum levels and atopic disorders (p > 0.05). Conclusion Our study in the Iranian population may support that T allele variants of rs6897932 and rs987106 are risk factors for atopy. However, serum levels of IL-7 were not significantly associated with a heightened risk of atopy.